Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Asset Writedowns and Impairment: 2012-2025

Historic Asset Writedowns and Impairment for Fennec Pharmaceuticals (FENC) over the last 1 years, with Sep 2025 value amounting to -$1.7 million.

  • Fennec Pharmaceuticals' Asset Writedowns and Impairment was N/A to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$318,000, marking a year-over-year change of. This contributed to the annual value of $3.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Asset Writedowns and Impairment of -$1.7 million as of Q3 2025, which was down 252.14% from $1.1 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $1.1 million during Q2 2025, with a 5-year trough of -$1.7 million in Q3 2025.
  • Over the past 2 years, Fennec Pharmaceuticals' median Asset Writedowns and Impairment value was $139,000 (recorded in 2024), while the average stood at -$79,500.